title: Can our society afford mechanical hearts?
abstract: Congestive heart failure afflicts 4 million people in the United States, with 400,000 deaths annually. Very little can be done for individuals with this condition, which is increasing in prevalence. The only hope is the promise of intervention with permanent circulatory support systems. Can we as a society afford the $3.1 billion that would be required to support every patient needing such a system? This cost represents an increase of 1/2 of 1% of the $662 billion per year expended for medical care. Fortunately, circulatory support systems do not necessarily represent an expense, but rather an investment that has a reasonable payback period. An investment in an individual of $100,000 for the device and implantation cost, coupled with an ongoing maintenance cost of $4,000 per year, can return to society an income greater in value than the investment. The payback period is strongly dependent on the earning power of the individual, as well as the amount of medical attention or complications experienced. An individual with an annual salary of $40,000 per year becomes a positive financial force in our society and increases the gross national product (GNP) within 5 years. The same individual with extensive medical complications and intermittent loss of salary can extend the payback period by an additional 2 years. Circulatory support systems have the potential of increasing our GNP, leading to a higher standard of living for the populace.
authors.affiliation: Thermo Cardiosystems Inc., Woburn, MA 01888-2697.
authors.forename: V L
authors.initials: VL
authors.lastname: Poirier
mesh_terms: D017048:Health Care Costs / Q000706:statistics & numerical data*; D005102:Health Expenditures / Q000706:statistics & numerical data*; D006333:Heart Failure / Q000191:economics* / Q000453:epidemiology; D016027:Heart Transplantation / Q000191:economics; D006354:Heart, Artificial / Q000191:economics*; D006353:Heart-Assist Devices / Q000191:economics*; D006801:Humans; D038622:Internationality; D040841:Resource Allocation; D013675:Technology, High-Cost; D009927:Tissue and Organ Procurement; D014481:United States / Q000453:epidemiology; D026712:Value of Life